Skip to main content
. 2023 Jan 30;14:1055671. doi: 10.3389/fimmu.2023.1055671

Figure 1.

Figure 1

DSP-0509 exhibited TLR7 selective agonistic activity (A) Chemical structure of DSP-0509. (B) TLR7/NF-κB/SEAP HEK 293 or TLR8/NF-κB/SEAP HEK 293 cells were treated with increasing concentrations of DSP-0509. Fluorescence in the supernatants was evaluated 19-24 h after compound addition. The values are mean ± S.E.M. (C) BMDCs were incubated with 1 μM DSP-0509 and collected after 1 h or 2 h and cytokine and chemokine levels were measured by qRT-PCR. (D) Human primary pDC were incubated with DSP-0509 for 4 h. IFNα concentration in supernatant was measured by ELISA. The values are the mean ± S.E.M. (E) Pharmacokinetics analysis was conducted in the CT26 cell-bearing Balb/c mouse. 5 mg/kg of DSP-0509 was administered intravenously. Blood was collected over time up to 24 h after administration. DSP-0509 concentration was determined by LC-MS/MS.